Bulletin
Investor Alert

Market Pulse Archives

Aug. 7, 2020, 9:12 a.m. EDT

NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Gilead Sciences Inc. (GILD)
  • X
    Merck KGaA (MRK)
  • X
    Eli Lilly & Co. (LLY)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s /zigman2/quotes/210293917/composite GILD +0.98% remdesivir with Merck KGaA's /zigman2/quotes/200605022/delayed DE:MRK +0.37% interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY +0.98% and Incyte Corp. /zigman2/quotes/204510994/composite INCY +0.64% 's Olumiant. Roche Holding AG /zigman2/quotes/206324342/delayed CH:ROG +0.92% has also said it will test its rheumatoid arthritis drug in combination with remdesivir.

/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 86.26
+0.84 +0.98%
Volume: 4.03M
Nov. 25, 2022 1:00p
P/E Ratio
32.62
Dividend Yield
3.39%
Market Cap
$108.19 billion
Rev. per Employee
$1.88M
loading...
/zigman2/quotes/200605022/delayed
DE : Germany: Frankfurt
175.55
+0.65 +0.37%
Volume: 101.00
Nov. 25, 2022 3:57p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
N/A
Rev. per Employee
€286,891
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 365.25
+3.53 +0.98%
Volume: 1.04M
Nov. 25, 2022 1:10p
P/E Ratio
54.86
Dividend Yield
1.07%
Market Cap
$347.05 billion
Rev. per Employee
$835,414
loading...
/zigman2/quotes/204510994/composite
US : U.S.: Nasdaq
$ 78.26
+0.50 +0.64%
Volume: 238,798
Nov. 25, 2022 1:00p
P/E Ratio
19.89
Dividend Yield
N/A
Market Cap
$17.41 billion
Rev. per Employee
$1.59M
loading...
/zigman2/quotes/206324342/delayed
CH : Switzerland: SWX
CHF 311.40
+2.85 +0.92%
Volume: 1.13M
Nov. 25, 2022 5:31p
P/E Ratio
17.62
Dividend Yield
2.99%
Market Cap
CHF255.73 billion
Rev. per Employee
CHF637,961
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.